C. Daniel Mullins
#167,687
Most Influential Person Now
Researcher
C. Daniel Mullins's AcademicInfluence.com Rankings
Download Badge
Chemistry
C. Daniel Mullins's Degrees
- PhD Pharmaceutical Health Services Research University of Maryland, College Park
- Masters Pharmaceutical Health Services Research University of Maryland, College Park
- Bachelors Pharmacy University of Maryland, College Park
Why Is C. Daniel Mullins Influential?
(Suggest an Edit or Addition)C. Daniel Mullins's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. (2007) (616)
- Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. (2007) (566)
- Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. (2012) (397)
- Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer (2014) (330)
- Cost-of-illness studies : a review of current methods. (2006) (176)
- Continuous patient engagement in comparative effectiveness research. (2012) (169)
- Personalized Strategies to Activate and Empower Patients in Health Care and Reduce Health Disparities (2016) (127)
- Health disparities: a barrier to high-quality care. (2005) (126)
- Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. (2017) (123)
- Barriers to self-management of diabetes: a qualitative study among low-income minority diabetics. (2014) (123)
- Cost-of-Illness Studies (2012) (119)
- The total economic burden of overactive bladder in the United States: a disease-specific approach. (2009) (115)
- Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. (2017) (106)
- Impact of patient involvement on clinical practice guideline development: a parallel group study (2018) (106)
- Practice Management Guidelines for Prophylactic Antibiotic Use in Tube Thoracostomy for Traumatic Hemopneumothorax: the EAST Practice Management Guidelines Work Group. Eastern Association for Trauma. (2000) (101)
- Dental visits to hospital emergency departments by adults receiving Medicaid: assessing their use. (2002) (94)
- A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. (2014) (90)
- Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. (1997) (88)
- Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. (2010) (86)
- Patients' attitudes about living donor transplantation and living donor nephrectomy. (2003) (83)
- Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0 (2017) (79)
- Framework for enhancing clinical practice guidelines through continuous patient engagement (2016) (78)
- Persistence, Switching, and Discontinuation Rates Among Patients Receiving Sertraline, Paroxetine, and Citalopram (2005) (75)
- Budget impact analysis: review of the state of the art (2005) (73)
- The development of direct-to-consumer prescription drug advertising regulation. (2002) (71)
- Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia (2008) (70)
- Patient-centeredness in the design of clinical trials. (2014) (70)
- Cost-of-Illness Studies: An Updated Review of Current Methods (2015) (69)
- Reasons for discharges against medical advice: a qualitative study (2010) (66)
- Practice management guidelines for prophylactic antibiotic use in penetrating abdominal trauma: the EAST Practice Management Guidelines Work Group. (2000) (66)
- Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. (2007) (64)
- Healthcare Rationing by Proxy (2012) (62)
- Effect of Age on Survival Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer (2009) (61)
- Impact of the 2004 Food and Drug Administration Pediatric Suicidality Warning on Antidepressant and Psychotherapy Treatment for New-Onset Depression (2010) (60)
- From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer (2012) (58)
- Discontinuation rates of topical glaucoma medications in a managed care population. (2002) (57)
- Do value thresholds for oncology drugs differ from nononcology drugs? (2015) (57)
- Cervical cancer outcomes analysis: impact of age, race, and comorbid illness on hospitalizations for invasive carcinoma of the cervix. (2000) (54)
- Dementia severity and the longitudinal costs of informal care in the Cache County population (2015) (52)
- Uncertainty in assessing value of oncology treatments. (2010) (51)
- Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol (2019) (50)
- Recommendations for patient engagement in guideline development panels: A qualitative focus group study of guideline-naïve patients (2017) (50)
- Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. (2005) (49)
- Dysnatremia is a Predictor for Morbidity and Mortality in Hospitalized Patients with COVID-19 (2021) (49)
- Exploring the relationship between Alzheimer's disease severity and longitudinal costs. (2012) (48)
- Exploring Donors' and Recipients' Attitudes about Living Donor Kidney Transplantation (2003) (48)
- The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer (2014) (47)
- Emerging standardization in pharmacoeconomics. (1998) (45)
- A survey of nephrologists' views on preemptive transplantation. (2008) (45)
- Exploring donors' and recipients' attitudes about living donor kidney transplantation. (2003) (44)
- Engaging hard-to-reach patients in patient-centered outcomes research. (2013) (43)
- The economic impact of laparoscopic living-donor nephrectomy on kidney transplantation (2003) (43)
- White paper: value of specialty certification in pharmacy. (2004) (43)
- Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer (2014) (42)
- Disparities in Access to Essential New Prescription Drugs between Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites (2006) (42)
- A Sustainable Strategy to Prevent Misuse of Antibiotics for Acute Respiratory Infections (2012) (39)
- Healthcare Rationing by Proxy Cost-Effectiveness Analysis and the Misuse of the $50 000 Threshold in the US (2009) (39)
- Using community-based participatory research in patient-centered outcomes research to address health disparities in under-represented communities. (2015) (38)
- Disparity implications of Medicare eligibility criteria for medication therapy management services. (2010) (38)
- Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare (2013) (36)
- The Direct Medical Costs of α1-Antitrypsin Deficiency* (2001) (36)
- Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. (2020) (35)
- Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. (2013) (35)
- Hospital admissions associated with nontraumatic dental emergencies in a Medicaid population. (2003) (34)
- Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials (2012) (34)
- Cost-effectiveness of a motivational intervention to reduce rapid repeated childbearing in high-risk adolescent mothers: a rebirth of economic and policy considerations. (2010) (33)
- Transitioning from learning healthcare systems to learning health care communities. (2018) (33)
- Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients: The Role of the Medical Oncologist Evaluation (2009) (33)
- Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. (2008) (32)
- Improving transparency to build trust in real‐world secondary data studies for hypothesis testing—Why, what, and how: recommendations and a road map from the real‐world evidence transparency initiative (2020) (32)
- Practice Management Guidelines for Prophylactic Antibiotic Use in Tube Thoracostomy for Traumatic Hemopneumothorax: The EAST Practice management Guidelines Work Group (2000) (32)
- Stakeholder engagement in patient-centered outcomes research: high-touch or high-tech? (2014) (32)
- Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome (2011) (31)
- The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): A Randomized Trial of the Effect of Education on Improving Blood Pressure Control in a Largely African American Population (2011) (31)
- Patient engagement and shared decision-making: What do they look like in neurology practice? (2016) (31)
- Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. (2010) (31)
- Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare (2015) (31)
- Effects of a Medicaid prior authorization policy for pregabalin. (2009) (30)
- Short-Term Impact of an Educational Program Promoting Live Donor Kidney Transplantation in Dialysis Centers (2008) (30)
- Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. (2015) (30)
- Drug therapy persistence and stroke recurrence. (2006) (30)
- Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. (2005) (29)
- Indirect cost of HIV infection in England. (2000) (29)
- Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. (2010) (29)
- Factors associated with hospitalization costs for patients with community-acquired pneumonia. (2003) (28)
- Variability and growth in spending for outpatient specialty pharmaceuticals. (2005) (28)
- Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. (2003) (27)
- Health care cost and utilization project analysis of comorbid illness and complications for patients undergoing hysterectomy for endometrial carcinoma (2001) (26)
- New Diagnosis of Hypertension among Celecoxib and Nonselective NSAID Users: A Population-Based Cohort Study (2007) (26)
- A Medicaid population's use of physicians' offices for dental problems. (2003) (26)
- The impact of pipeline drugs on drug spending growth. (2001) (26)
- Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study (2013) (26)
- Center effects in anemia management of dialysis patients. (2007) (26)
- Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. (2010) (26)
- Health disparities in staging of SEER-medicare prostate cancer patients in the United States. (2010) (26)
- Major Components of the Direct Medical Costs of α1-Antitrypsin Deficiency (2003) (25)
- Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. (1999) (25)
- Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study (2015) (25)
- PHARMACEUTICAL CARE INTERVENTION DOCUMENTATION PROGRAM AND RELATED COST SAVINGS AT A UNIVERSITY HOSPITAL (1999) (25)
- Patterns and Correlates of Linkage to Appropriate HIV Care After HIV Diagnosis in the US Medicaid Population (2013) (25)
- Comparative Effectiveness of Different Chemotherapeutic Regimens on Survival of People Aged 66 and Older with Stage III Colon Cancer: A “Real World” Analysis Using Surveillance, Epidemiology, and End Results–Medicare Data (2011) (25)
- Rating of Included Trials on the Efficacy-Effectiveness Spectrum: development of a new tool for systematic reviews. (2017) (24)
- Value Assessment at the Point of Care: Incorporating Patient Values throughout Care Delivery and a Draft Taxonomy of Patient Values. (2017) (24)
- The Breathmobile program: a good investment for underserved children with asthma. (2010) (23)
- Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases (2011) (23)
- Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods (2015) (23)
- Perspectives on electronic medical records adoption: electronic medical records (EMR) in outcomes research (2010) (23)
- Chemotherapy Treatment and Survival in Older Women with Estrogen Receptor–Negative Metastatic Breast Cancer: A Population‐Based Analysis (2011) (22)
- Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy. (2019) (22)
- "Ten commandments" for conducting comparative effectiveness research using "real-world data". (2011) (21)
- An Economic Evaluation of Triptan Products for Migraine (2005) (21)
- Impact of an educational intervention for secondary prevention of myocardial infarction on Medicaid drug use and cost. (2004) (20)
- Economic disparities in treatment costs among ambulatory Medicaid cancer patients. (2004) (20)
- Patient preferences for venous thromboembolism prophylaxis after injury: a discrete choice experiment (2017) (20)
- Comparison of first refill rates among users of sertraline, paroxetine, and citalopram. (2006) (20)
- A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting (2012) (20)
- Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer. (2009) (20)
- Medication access through patient assistance programs. (2006) (20)
- Skeletal-related events and mortality among older men with advanced prostate cancer. (2014) (19)
- Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using Surveillance, Epidemiology and End Results (SEER)‐Medicare data (2012) (19)
- Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer. (2012) (19)
- Using Bayesian Adaptive Trial Designs for Comparative Effectiveness Research: A Virtual Trial Execution. (2016) (19)
- The direct medical costs of alpha(1)-antitrypsin deficiency. (2001) (19)
- Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report. (2020) (18)
- Effect of initial ziprasidone dose on treatment persistence in schizophrenia (2006) (18)
- Major components of the direct medical costs of alpha1-antitrypsin deficiency. (2003) (18)
- Health disparities research--a model for conducting research on cancer disparities: characterization and reduction. (2002) (18)
- Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative study. (2014) (18)
- Racial Differences in Hospital Discharge Disposition among Stroke Patients in Maryland (2007) (17)
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations (2022) (17)
- The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case–control study (2010) (17)
- Hospital Center Effect for Laparoscopic Colectomy Among Elderly Stage I-III Colon Cancer Patients (2013) (17)
- A Systematic Review of Entrepreneurship in Pharmacy Practice and Education (2019) (16)
- Early assessment of the 10-step patient engagement framework for patient-centred outcomes research studies: the first three steps (2017) (16)
- New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs. (2005) (16)
- Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. (2008) (16)
- Understanding preferences for type 2 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods study (2016) (16)
- Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. (2005) (16)
- The potential impact of comparative effectiveness research on the health of minority populations. (2010) (16)
- Medicaid Coverage and Utilization of Adult Dental Services (2004) (16)
- Selective cyclooxygenase-2 inhibition and cardiovascular effects: An observational study of a Medicaid population (2005) (16)
- Understanding heterogeneity of treatment effect in prostate cancer (2015) (16)
- Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible? (2002) (15)
- What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism (2019) (15)
- Haemodialysis patients' readiness to pursue live donor kidney transplantation. (2008) (15)
- Comparative and cost‐effectiveness of oxaliplatin‐based or irinotecan‐based regimens compared with 5‐fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients (2012) (15)
- Participation and consultation engagement strategies have complementary roles: A case study of patient and public involvement in clinical practice guideline development (2019) (15)
- Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis (2019) (15)
- Lessons learned from community-based minority health care serving system participation in an NIH clinical trial. (2011) (15)
- Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion. (2008) (14)
- Development of a guidance for including patient-reported outcomes (PROs) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER). (2011) (14)
- College students' perceived benefit-to-risk tradeoffs for nonmedical use of prescription stimulants: Implications for intervention designs. (2018) (14)
- Age-related racial disparities in prostate cancer patients: A systematic review (2017) (14)
- Resources and use of the intensive care unit in patients who undergo surgery for ovarian carcinoma (2002) (14)
- Health plans' strategies for managing outpatient specialty pharmaceuticals. (2006) (14)
- Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C Patients (2017) (14)
- Perception of Barriers to the Diagnosis and Receipt of Treatment for Neuropsychiatric Disturbances After Traumatic Brain Injury. (2017) (14)
- What are outcomes? (1996) (14)
- Future of Patients in Healthcare Evaluation: The Patient-Informed Reference Case. (2019) (14)
- Comparisons of Hypertension-Related Costs from Multinational Clinical Studies (2012) (14)
- Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system. (2008) (14)
- Study protocol testing toolkit versus usual care for implementation of screening, brief intervention, referral to treatment in hospitals: a phased cluster randomized approach (2018) (13)
- Disparities in prevalence rates for lung, colorectal, breast, and prostate cancers in Medicaid. (2004) (13)
- Incidence versus prevalence modeling in pharmacoeconomics (2002) (13)
- Pharmacy Benefit Management (2002) (13)
- Rifampicin for Continuation Phase Tuberculosis Treatment in Uganda: A Cost-Effectiveness Analysis (2012) (13)
- Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer. (2012) (13)
- BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles (2016) (13)
- Medical Expenditure Panel Survey: a valuable database for studying racial and ethnic disparities in prescription drug use. (2008) (12)
- A qualitative evaluation of a citywide Community Health Partnership program. (2012) (12)
- The value of atorvastatin over the product life cycle in the United States. (2011) (12)
- Racial disparities in urologist visits among elderly men with prostate cancer: A cohort analysis of patient‐related and county of residence‐related factors (2014) (12)
- Prescribing trends and drug budget impact of the ARBs in the UK. (2009) (12)
- Discriminatory power of a 25-item distress screening tool: a cross-sectional survey of 251 cancer survivors (2014) (12)
- Multispecialist Care and Mortality in Hepatocellular Carcinoma (2015) (12)
- What are outcomes (1996) (11)
- Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers. (2013) (11)
- Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings. (2012) (11)
- Readmissions After Unauthorized Discharges in the Cardiovascular Setting (2011) (11)
- Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. (2002) (11)
- Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States. (2018) (11)
- Short-term impact of an educational program promoting live donor kidney transplantation in dialysis centers. (2008) (10)
- Resource utilization for patients undergoing hysterectomy with or without lymph node dissection for endometrial cancer. (2002) (10)
- Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. (2011) (10)
- Emerging Good Practices for Transforming Value Assessment: Patients' Voices, Patients' Values. (2018) (10)
- PEER-REVIEWED JOURNAL EDITORS’ VIEWS ON REAL-WORLD EVIDENCE (2018) (10)
- Double counting and the reporting of cost per event avoided. (2006) (10)
- Principles of economics crucial to pharmacy students' understanding of the prescription drug market. (2008) (10)
- Continuous patient engagement in cardiovascular disease clinical comparative effectiveness research (2016) (9)
- Criteria to Request Pharmacoeconomic Data and Data Sources for Hospital Formulary Decisions (2001) (9)
- Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis. (2001) (9)
- “I’m a Little More Trusting”: Components of Trustworthiness in the Decision to Participate in Genomics Research for African Americans (2020) (9)
- The use of health services among elderly patients with stage IV prostate cancer in the initial period following diagnosis. (2014) (9)
- Patients’ early engagement in research proposal development (PEER-PD): patients guiding the proposal writing (2019) (9)
- The economic burden associated with SSRI treatment failure in a managed care population (2008) (9)
- Site engagement for multi-site clinical trials (2020) (8)
- If patients are the true north, patient-centeredness should guide research (2018) (8)
- Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis (2017) (8)
- Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index. (2007) (8)
- Policy implications of drug importation. (2007) (8)
- PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients (2021) (8)
- Pulmonary artery intimal injury associated with blunt trauma (2009) (8)
- Six ways to foster community-engaged research during times of societal crises (2020) (7)
- Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids (2018) (7)
- Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC) (2007) (7)
- Economic Analysis of Triptan Therapy for Acute Migraine: A Medicaid Perspective (2007) (7)
- What works when: mapping patient and stakeholder engagement methods along the ten-step continuum framework. (2021) (7)
- Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers, Peter J. Neumann (Ed.). Oxford University Press Oxford, U.K. (2004), 224, £19.99 ISBN 0-19-517186-1 (2006) (7)
- Clinic visits and prescribing patterns among veterans affairs maryland health care system dementia patients (2010) (7)
- Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients. (2016) (7)
- Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. (2016) (7)
- Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease (2017) (7)
- Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients (2013) (7)
- Practice Management Guidelines for Prophylactic Antibiotic Use in Penetrating Abdominal Trauma: The EAST Practice Management Guidelines Work Group (2000) (7)
- Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer (2018) (7)
- A framework for pharmacist-assisted medication adherence in hard-to-reach patients. (2015) (6)
- Therapy (Tx) of locally advanced (LA) NSCLC in the elderly: Analysis of 6,325 patients from Surveillance, Epidemiology and End Results (SEER)-Medicare (2008) (6)
- HP6: THE IMPACT OF PIPELINE DRUGS ON UNITED STATES DRUG EXPENDITURE GROWTH TRENDS (2001) (6)
- Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing (2019) (6)
- Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients (2014) (6)
- Does Earlier Headache Response Equate to Earlier Return to Functioning in Patients Suffering from Migraine? (2006) (6)
- Advancing community-engaged research: increasing trustworthiness within community-academic partnerships. (2020) (6)
- Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients (2014) (5)
- Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. (2011) (5)
- Bone metastasis (BM) based on SEER registry versus Medicare claims among metastatic prostate cancer (PCa) patients (pts) in SEER-Medicare. (2012) (5)
- Chemotherapy (C) and survival among 21,441 elderly (E) patients (pts) with advanced (adv) NSCLC: Analysis of SEER-Medicare claim data 1997-2002 (2008) (5)
- Recommendations for Good Procedural Practices for Real-World Data Studies of Treatment Effectiveness and/or Comparative Effectiveness Designed to Inform Health Care Decisions: Report of the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making (2017) (5)
- How Do US Health Care Payers React to and Use Pharmacoeconomic Information? (2011) (5)
- Societal implications of the pharmacoeconomics of α1-antitrypsin deficiency (2002) (5)
- Pharmapreneur – Defining a Framework for Entrepreneurship in Pharmacy Education (2019) (5)
- Pragmatic patient engagement in designing pragmatic oncology clinical trials. (2021) (5)
- A Simplified Approach to Teaching Markov Models (1996) (5)
- Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter? (2016) (5)
- An Approach to Adapting a Community-Based Cancer Control Intervention to Organizational Context (2020) (5)
- Developing a collaborative study protocol for combining payer-specific data and clinical trials for CER. (2011) (5)
- Association of Postoperative Infections After Fractures With Long-term Income Among Adults (2021) (5)
- KRAS tests utilizations, biologics uptakes, and disparities in access by demographic groups among metastatic colon cancer patients. (2015) (4)
- Engaging Stakeholders to Optimize Sleep Disorders' Management in the U.S. Military: A Qualitative Analysis. (2021) (4)
- Intervention for decreasing excessive acetaminophen use in Pennsylvania Medicaid recipients. (2004) (4)
- Diabetes control through an educational intervention. (2014) (4)
- Strategies to Prevent MRSA Transmission in Community-Based Nursing Homes: A Cost Analysis (2016) (4)
- Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials (2021) (4)
- Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone (2017) (4)
- Combining the Principles of Epidemiology and Economics 1 (1994) (4)
- Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancer. (2017) (3)
- Prescription drug spending trends for the privately insured in Maryland, 2000-2001. (2004) (3)
- Pharmacists' Assessment of Facets of Health Literacy in Pharmacy Practice Settings (2011) (3)
- Patient and Provider Acceptability of a Patient Preauthorized Concealed Opioid Reduction. (2021) (3)
- Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools. (2019) (3)
- Pragmatic randomized trial evaluating pre-operative aqueous antiseptic skin solution in open fractures (Aqueous-PREP): the feasibility of a cluster randomized crossover study (2021) (3)
- Comparisons of changes over time in per capita health expenditures across racial and ethnic groups (2010) (3)
- Health care cost of analgesic use in hypertensive patients. (2004) (3)
- Cost effectiveness of kinetic therapy in preventing nosocomial lower respiratory tract infections in patients suffering from trauma. (2002) (3)
- Survival benefit associated with the number of chemotherapy/biologic treatment lines in 5,129 elderly metastatic colon cancer patients. (2013) (3)
- Evaluation of Tigecycline Efficacy and Post-Discharge Outcomes in a Clinical Practice Population with Complicated Intra-Abdominal Infection: A Propensity Score–Matched Analysis (2016) (3)
- Overview of Cancer Economics (1999) (3)
- Effect of age on survival benefit of adjuvant chemotherapy in elderly stage III colon cancer patients: a population-based analysis (2008) (3)
- Rising copayments and the kinked demand curve (2003) (3)
- Veteran engagement in opioid tapering research: a mission to optimize pain management (2021) (3)
- Epidemiology of public transportation use among older adults in the United States (2022) (3)
- Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 (2021) (3)
- Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial (2022) (3)
- A LITERATURE REVIEW OF FACTORS AFFECTING PRICE AND COMPETITION IN THE GLOBAL PHARMACEUTICAL MARKET (2016) (3)
- Evolving Use of Real-World Evidence for Devices: Good for Patients, Good for Policy Makers. (2019) (3)
- Health-related quality of life as a potential predictor in chronic obstructive lung disease patients (2007) (3)
- The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model. (2013) (3)
- Comparative analysis of second and subsequent chemotherapy lines on short- and long-term survival of elderly Medicare metastatic colon cancer patients. (2013) (2)
- Is there evidence of diminishing disparities in treatment (tx) with adjuvant (adj) chemotherapy (Ch) among elderly (E) stage 3 colon cancer (CC) patients (pts)? An analysis of 8,374 pts from SEER-Medicare data (2008) (2)
- Low-Risk Papillary Thyroid Cancer: Treatment De-Escalation and Cost Implications. (2022) (2)
- Active Duty Service Members, Primary Managers, and Administrators' Perspectives on a Novel Sleep Telehealth Management Platform in the U.S. Military Healthcare System. (2022) (2)
- Heterogeneity of treatment effects (HTE) in stage IV prostate cancer (S4PC). (2012) (2)
- Threshold denial rates in prior authorization prescription programs (2004) (2)
- PCVD14: USE OF CONFIDENCE INTERVALS TO ESTIMATE THE COST-EFFECTIVENESS OF ABCIXIMAB (1999) (2)
- Pharmaceutical Market Impact of the Early 1990's Health Care Debate (2001) (2)
- Applications of Pharmacoeconomics for Managed Care Pharmacy (2015) (2)
- Value of Propensity Score Matching for Equalizing Comparator Groups in Observational Database Studies: A Case Study in Anti-infectives. (2016) (2)
- The need to address uncertainty and heterogeneity of treatment effect in clinical studies. (2010) (2)
- Impact of the fourth hurdle on the international pharmaceutical industry (2003) (2)
- New perspectives on overactive bladder and its treatment. Introduction. (2009) (2)
- Continuous patient engagement in comparative effectiveness research (CER): An application in cardiovascular disease (CVD) (2014) (2)
- The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19) (2020) (2)
- Oncology Pharmacy Management and the Evolving Role of Managed Care: Recommendations for a Changing Environment with a Focus on Multiple Myeloma (2015) (2)
- Querying stakeholders to inform comparative effectiveness research. (2017) (2)
- Patient and stakeholder engagement learnings: PREP-IT as a case study. (2021) (2)
- The peer-review process: gifts of time. (2005) (2)
- The increasing use of the internet for obtaining medical information. (2004) (2)
- The Affordable Care Act, health care reform, prescription drug formularies and utilization management tools. (2015) (2)
- Burden and Timing of First and Subsequent Skeletal Related Events (SRES) in United States Elderly Men with Metastatic Prostate Cancer (MPC) (2014) (2)
- Limitations and Challenges of Conducting Budget Impact Analyses in Rare Diseases: A Case Study of Alpha-1 Antitrypsin Deficiency. (2020) (2)
- Variation in the Length of Radiation Therapy Among Men Diagnosed With Incident Metastatic Prostate Cancer (2013) (2)
- Patient and Stakeholder Engagement in Designing Pragmatic Clinical Trials (2017) (2)
- Risk of Heart Failure with the Use of Thiazolidinediones within a Medicaid Population (2005) (2)
- Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States (2019) (2)
- Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma. (2022) (1)
- The impact of COVID-19 restrictions on participant enrollment in the PREPARE trial (2022) (1)
- Total thyroidectomy is more cost-effective than radioactive iodine as an alternative to antithyroid medication for Graves' disease. (2022) (1)
- The new administration and Medicare reform. (2001) (1)
- Population Health and the Patient (2015) (1)
- Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. (1998) (1)
- PCV15 NEW DIAGNOSIS OF HYPERTENSION AMONG CELECOXIB AND NON-SELECTIVE NSAID USERS:A POPULATION-BASED COHORT STUDY (2007) (1)
- The visibility and divisibility of quality-adjusted life-years. (2005) (1)
- Access to pharmaceuticals in the post‐Medicare Part D era (2010) (1)
- PCV18 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN (2004) (1)
- Prevalence of fractures among men with stage IV prostate cancer (S4PC). (2014) (1)
- PIN17 COST-EFFECTIVENESS MODELING OF TREATMENT APPROACHES TO HEPATITIS C: A MANAGED CARE PERSPECTIVE (2004) (1)
- PMH5 INFLUENCE OF PSYCHIATRIC COMORBIDITY AND POLYPHARMACY ON HOSPITALIZATION AND EXPENDITURES AMONG SECOND GENERATION ANTIPSYCHOTIC USERS WITH METABOLIC SYNDROME (2010) (1)
- Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What? (2017) (1)
- Characteristics of triple-negative metastatic breast cancer among older adults: A population-based analysis. (2010) (1)
- PMH66 COMPARISON OF FIRST REFILL RATES AMONG BRANDED SSRI USERS (2004) (1)
- PCN31 DIRECT MEDICAL COSTS OF ELDERLY PATIENTS WITH STAGE III COLON CANCER DURING FIRST-LINE VERSUS SECOND-LINE CHEMOTHERAPY (2011) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Physician prescribing and the hippocratic oath. (2005) (1)
- Moving from General Predictors to Patient-Specific Indicators of Nonadherence (2008) (1)
- It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction. (2011) (1)
- Increasing utilization of endoscopic local excision for early-stage gastric cancers in the United States. (2022) (1)
- Which orthopaedic trauma patients are likely to refuse to participate in a clinical trial? A latent class analysis (2019) (1)
- Multispecialty care among hepatocellular carcinoma patients in SEER-Medicare. (2012) (1)
- Cost Analysis Of Skeletal Related Events Among Elderly Men With Stage Iv Metastatic Prostate Cancer In Seer-Medicare (2013) (1)
- Patient-Centric Structural Determinants of Adherence Rates Among Asthma Populations: Exploring the Potential of Patient Activation and Encouragement Tool TRUSTR to Improve Adherence (2020) (1)
- Patient copayments and patient-reported outcomes (2002) (1)
- Characteristics of stage III and IV M0 prostate cancer (PCa) patients in SEER-Medicare who develop bone metastasis (BM) following diagnosis. (2012) (1)
- Who receives chemotherapy: An analysis of stage IV prostate cancer (PCa) patients in SEER-Medicare. (2010) (1)
- The role of geography in health care dissemination (2007) (1)
- The Use Of Transarterial Chemoembolization For Treating Hepatocellular Carcinoma In The Seer-Medicare Population (2013) (1)
- Longitudinal versus Cross-Sectional Methodology for Estimating the Economic Burden of Breast Cancer (2012) (1)
- PG13 MAJOR GI EVENTS AMONG ELDERLY CHRONIC USERS OF COX-2SAND NON-SELECTIVE NSAIDS, WITH/WITHOUT ASPIRIN (2006) (1)
- Impact of Food and Drug Administration (FDA) paediatric antidepressant warnings on stock prices of pharmaceutical manufacturers (2010) (1)
- Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guideline (GL) drug therapy recommendations for metastatic breast cancer: An analysis from the commercial managed care claims database PharMetrics (PM). (2010) (1)
- Applying Oncology Formulary and Benefit Design Innovations to the Management of Multiple Myeloma in the Managed Care Setting (2015) (1)
- Supply and demand in the decision-making process of pharmaceutical consumers: The starbucks versus dunkin' donuts dilemma (2009) (1)
- Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. (2011) (1)
- Definition of end-of-life period and Quality Benchmarks in Terminal Cancer Care: a Literature Review (2015) (1)
- Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C (2015) (1)
- A pragmatic randomized trial evaluating pre-operative aqueous antiseptic skin solutions in open fractures (Aqueous-PREP): statistical analysis plan (2022) (1)
- Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C Patients. (2015) (1)
- Comparative analysis of treatments, utilization, and survival benefit in HCC patients: A real-world analysis of SEER Medicare. (2012) (1)
- Correction to: Cluster identification, selection, and description in Cluster randomized crossover trials: the PREP-IT trials (2020) (1)
- Cost-Effectiveness Of Grazoprevir / Elbasvir In Patients With Chronic Hepatitis C Virus (2016) (1)
- Cluster-randomized trial comparing organizationally tailored versus standard approach for integrating an evidence-based cancer control intervention into African American churches. (2021) (1)
- Similar values, different expectations: How do patients and providers view ‘health’ and perceive the healthcare experience? (2022) (1)
- PIN56 Rehospitalization and Costs Among Patients Treated With Linezolid Versus Vancomycin Following Hospitalization for Pneumonia in the Real-World Setting (2012) (1)
- Cost Effectiveness of Abciximab During Routine Medical Practice (2000) (1)
- The impact of comorbidity on costs and effects of second-line treatment among elderly metastatic colon cancer patients. (2014) (1)
- Research is needed on the difficult‐to‐cure population of hepatitis C virus patients with disability (2015) (1)
- Physician referral patterns among men with advanced prostate cancer. (2014) (1)
- Treatment Modalities For Hepatocellular Carcinoma: Cumulative Expenditures And Survival In Seer-Medicare (2013) (1)
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. (2022) (1)
- The impact of clinical therapies (2003) (1)
- Discriminatory power of a 25-item distress screening tool CancerSupport Source: A cross-sectional study of 251 cancer survivors. (2013) (1)
- Are Communities Willing to Transition Into Learning Health Care Communities? A Community-Based Participatory Evaluation of Stakeholders’ Receptivity (2021) (1)
- Affordable versus acceptable drug prices (2002) (1)
- Pharmaceutical Restrictions (2001) (1)
- How does dementia severity affect the costs of dementia care? (2013) (1)
- PCN43 INITIAL COSTS OF TREATMENT AMONG STAGE IV PROSTATE CANCER (PCA) CHEMOTHERAPY PATIENTS IN SEER-MEDICARE (2010) (1)
- Data Gathering: Early and Often (2007) (1)
- DO JOURNAL EDITORS PERCEIVE REAL-WORLD EVIDENCE AS VALUABLE? (2016) (1)
- PCN62 FIRST YEAR COST EXPENDITURES ASSOCIATED WITH HEAD AND NECK CANCER DIAGNOSIS IN THE U.S. MANAGED CARE POPULATION (2009) (1)
- PCN106 Development of a Guidance for Including Patient-Reported Outcomes (PROs) in Late-Phase Adult Clinical Trials of Oncology Drugs for Comparative Effectiveness Research (CER) (2012) (1)
- Sound public health policy: Focusing on saving the most lives possible. (2005) (0)
- PRM174 The Need to Conduct Future Research on the Benefit of the Prostate Specific Antigen Screening Test Using the Value of Information Framework (2012) (0)
- Prostate cancer (PC) follow-up and treatment by race in an equal access health system: A pilot study. (2013) (0)
- Medical Costs of Alpha-1 Antitrypsin Deficiency: Evidence From Real-World Claims Data (2017) (0)
- PCN6: CAN ICD-9 CODES BE USED AS A PROXY FOR DISEASE STAGING IN ECONOMIC EVALUATIONS? (2001) (0)
- Understanding Caregiver Preferences for Treating Children with Intellectual and Cognitive Disabilities and a Mental Illness (2019) (0)
- The authors reply ... Formulary decision-making should rely on the best available evidence (2006) (0)
- PCN60 COST-EFFECTIVENESS OF OXALIPLATIN AND IRINOTECAN BASED COMBINATION THERAPY COMPARED WITH 5FU/LV FOR THE TREATMENT OF US ELDERLY ADVANCED COLON CANCER PATIENTS (2010) (0)
- Skeletal-Related Events And Mortality Among Seer-Medicare Patients With Metastatic Prostate Cancer: The Implications Of Measurement Approach (2013) (0)
- PMS30 ADHERENCE TO DULOXETINE AND HOSPITAL UTILIZATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND CHRONIC PAIN (2010) (0)
- Does first-line treatment impact the cost-effectiveness of second-line treatment for elderly metastatic colon cancer patients? (2014) (0)
- Real-world treatment patterns and the uptake of biologics in elderly medicare patients with metastatic colon cancer. (2015) (0)
- Comparative effectiveness of adjuvant oxaliplatin and irinotecan-based chemotherapy regimens among elderly stage III colon cancer patients completing 12 cycles. (2010) (0)
- Recommendations for designing comparative effectiveness studies in oncology. (2011) (0)
- PCN34 Descriptive Costs of Chemotherapy Treatment for Stage 3 and Stage 4 Colon Cancer (2012) (0)
- The impact of docetaxel (D) in an older population of patients with advanced prostate cancer (PC): A simulation study using TAX327 and SEER Medicare data. (2009) (0)
- Disparities and trends in prostate cancer staging over time (2008) (0)
- PCR39 Patient and Caregiver Diversity in FDA Patient Engagement Activities and CBER-Regulated Therapeutics: A Review of the Literature (2022) (0)
- DB4 ECONOMIC EVALUATION OF THIAZOLIDINEDIONES AS ADD-ON THERAPY FOR TREATMENT OF TYPE 2 DIABETIC PATIENTS IN THE TAIWANESE NATIONAL HEALTH INSURANCE SYSTEM (2010) (0)
- PDB63 THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS: WAS THERE A DIFFERENTIAL EFFECT? (2009) (0)
- A LITERATURE REVIEW OF STUDY DESIGN ELEMENTS IN COST-EFFECTIVENESS ANALYSES (2016) (0)
- Use of biologics in addition to chemotherapy in the treatment of elderly Medicare patients with stage IV metastatic colon cancer. (2013) (0)
- 792 Hospital Center Effect for Laparoscopic Colectomy Among Elderly Stage I-III Colon Cancer Patients (2013) (0)
- PCN66 COST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY AMONG U.S. BREAST CANCER PATIENTS (2009) (0)
- Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guidelines (GL) for imaging work-up of patients with metastatic breast cancer: An analysis from the commercial managed care claims PharMetrics (PM) and SEER/Medicare (SM) databases. (2010) (0)
- Clinical Decision Support At Time Of Prescribing To Decrease Inappropriate Antibiotics Prescribing For Treatment Of Acute Respiratory Infections (2010) (0)
- PSR6 STROKE RECURRENCE AND PERSISTENCE ON DRUG THERAPY IN A MEDICAID POPULATION (2005) (0)
- PMH65 SECOND SSRIS SWITCHING AND DISCONTINUATION AFTER FLUOXETINE INITIAL THERAPY (2004) (0)
- Introduction: Economics of the Pharmaceutical Industry: Essays in Honor of Henry G. Grabowski (2011) (0)
- PMH33 FACTORS INFLUENCING ZIPRASIDONE PRESCRIBED DOSES AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA (2005) (0)
- Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis. (2018) (0)
- PMD21 The Association of Major Adverse LIMB Events and Combination Stent and Atherectomy in Patients Undergoing Revascularization for Lower Extremity Peripheral Artery Disease (2021) (0)
- Abstract P204: Reasons for Unauthorized Discharges Among Patients With Cardiovascular Disease: A Qualitative Study (2011) (0)
- Incremental cost (IC) analysis of skeletal related events (SREs) among elderly men with stage IV metastatic (M1) prostate cancer (PCa). (2013) (0)
- Frequency of second- and third-line treatment among elderly Medicare stage IV colon cancer patients. (2012) (0)
- Sociodemographic factors impacting clinical trial enrollment and outcomes in stage III non-small cell lung cancer (NSCLC). (2014) (0)
- Patterns of Psychotropic Medication Use among Individuals with Traumatic Brain Injury. (2019) (0)
- An algorithm to identify delivery of palliative radiation therapy using health care claims data: A proof of concept application of data visualization tools in the prostate cancer (PCa) setting. (2014) (0)
- PCV81 ASSESSING THE IMPACT OF INCORPORATING PATIENT KNOWLEDGE AND BELIEFS INTO ANTICOAGULATION THERAPY MANAGEMENT SERVICES (2008) (0)
- College Students' Preferences for Components of a Campus-Sponsored Program to Reduce Nonmedical Use of Prescription Stimulants (2018) (0)
- Predictors and prognostic implication of pathologic fracture (PF), spinal cord compression (SCC), and bone surgery (BS) following diagnosis of metastatic prostate cancer (PCa). (2013) (0)
- Visit and treatment patterns over time among elderly patients (pts) with M1 prostate cancer (PC): An analysis using SEER-Medicare. (2009) (0)
- PCN60 COSTS OF CARE FOR ELDERLY METASTATIC PROSTATE CANCER PATIENTS OVER TIME (2009) (0)
- PCV51 THE VALUE OF ATORVASTATIN OVER THE PRODUCT LIFE CYCLE (2011) (0)
- S1: IMPACT OF COMMUNITY-ACQUIRED PNEUMONIA TREATMENT GUIDELINES ON LENGTH OF STAY AND COST (2000) (0)
- PHP23 EFFECT OF INSURANCE TYPE ON HEALTH PLANS' SPENDING ON SPECIALTY PHARMACEUTICALS: AN EMPIRICAL ANALYSIS (2006) (0)
- ELICITING PATIENT PREFERENCES FOR TREATMENT OUTCOMES IN SYSTEMIC LUPUS ERYTHMATOSUS (2016) (0)
- Is the number of TACE treatments in HCC patients associated with improved survival? A SEER-Medicare population analysis. (2012) (0)
- Prevalence of first and subsequent skeletal-related events (SREs) in U.S. elderly patients with metastatic prostate cancer (mPC). (2014) (0)
- PMH39 COMPARATIVE ANALYSIS OF DISCONTINUATION HAZARD FOR ATYPICAL ANTIPSYCHOTICS (2006) (0)
- Use of Bone-Modifying Agents Following Androgen Deprivation Therapy for Medicare Non-Metastatic Prostate Cancer Patients (2014) (0)
- PCN163 HEALTHCARE RESOURCE UTILIZATION AND COUNTY-LEVEL DETERMINANTS OF FOLLICULAR LYMPHOMA STAGE AT DIAGNOSIS (2019) (0)
- P-394: Assessment of the impact of valdecoxib on systolic blood pressure in clinial practice (2005) (0)
- HE3 DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES (2006) (0)
- PCV134 READMISSIONS AFTER UNAUTHORIZED DISCHARGES IN THE CARDIOVASCULAR SETTING (2010) (0)
- PNS206 CAN WE IMPROVE THE ESTIMATION OF CENSORED COST DATA USING RANDOM FORESTS? (2019) (0)
- PMH13 ASSOCIATION OF MEDICATION PERSISTENCE AND HEALTH-CARE UTILIZATION IN HIGH-COST PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE OR VENLAFAXINE XR (2010) (0)
- Heterogeneity of Treatment Effect of Androgen Deprivation Therapy In Patients With Incident Metastatic Prostate Cancer (2015) (0)
- PCV66 COSTS ASSOCIATED WITH DISCHARGES AGAINST MEDICAL ADVICE IN A CVD POPULATION (2010) (0)
- Early Assessment Of The 10-Step Patient Engagement Framework For Patient-Centered Outcomes Research Studies: The First 3 Steps (2016) (0)
- Association of individual low-income status and area deprivation with mortality in multiple myeloma. (2023) (0)
- PMD13 A Framework for the Creation of Objective Performance Criteria Among Medical Devices: Reflections from Stakeholders (2021) (0)
- PMH56 STARTING DOSE AND PERSISTENCE FOR ZIPRASIDONE USERS IN MEDICAID (2005) (0)
- PCV1 Modern Methods of Delivering Adjuvant Radiotherapy Treatment and the Risk of Cardiac Injury in Breast Cancer (2012) (0)
- AI4 Comparing Machine-Learning Methods for the Prediction of Major Adverse Limb Events and Mortality after a Percutaneous Intervention (2021) (0)
- Health services utilization differences between patients with metastatic (M1) and nonmetastatic (M0) prostate cancer (PCa). (2013) (0)
- MSR72 Collaborative, Multisectoral, and Multidisciplinary Approach to Enhance FDA One Health Initiative Communication Strategies (2022) (0)
- PCN12 TIMING OF PHYSICIAN VISITS AND THE IMPACT ON SURVIVAL AMONG SEER-MEDICARE PATIENTS WITH STAGE IV PROSTATE CANCER (2009) (0)
- RS3 THE COST-EFFECTIVENESS OF TIOTROPIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2006) (0)
- Time to follow-up and treatment in patients with newly diagnosed prostate cancer (PC) across clinical stages in an equal access health system. (2013) (0)
- Payers’ views on Heterogeneity of treatment effect in Oncology (2015) (0)
- Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Report of the ISPOR Drug Cost Task Force - Part IV: Medicare, Medicaid and Other US Government Payers Perspectives (2008) (0)
- Second- and third-line chemotherapy regimens in elderly Medicare stage IV colon cancer patients. (2012) (0)
- MP78-04 ORAL AND INTRAVENOUS BISPHOSPHONATE USE FOLLOWING ANDROGEN DEPRIVATION THERAPY AMONG MEDICARE BENEFICIARIES WITH NON-METASTATIC PROSTATE CANCER (2014) (0)
- PCV133 THE COST-EFFECTIVENESS OF GENOTYPING CYP2C19 TO GUIDE ANTIPLATELET THERAPY SELECTION (2010) (0)
- Patterns of use of docetaxel in stage IV prostate cancer (PCa) patients in SEER-Medicare. (2010) (0)
- Questionnaire to Assess the Relevance and Credibility of a Prospective Observational Study (2016) (0)
- PMH8 SWITCHING & DISCONTINUATION OF SERTRALINE, PAROXETINE AND CITALOPRAM THERAPY (2004) (0)
- MM7 Issues in Developing Economic Models for Managed Care: The Case of Osteoporosis Prevention (1998) (0)
- CN4 - COMPARISON OF MACHINE LEARNING ALGORITHMS FOR THE PREDICTION OF MISSING CROSS-SECTIONAL COST DATA (2018) (0)
- Receipt of Treatment for Depression Following Traumatic Brain Injury (2020) (0)
- Eliciting Treatment Preferences in Low-Risk Thyroid Cancer through Experience-Driven Clinical Vignettes: A Stakeholder-Engaged Approach (2023) (0)
- Treatment duration and survival time: Does only the last line matter? (2015) (0)
- Modeling the Annual Cost of Postmenopausal Prevention Therapy Using Hormone Replacement Therapy, Raloxifene, and Alendronate: P-24. (1999) (0)
- Advantages Of Bayesian Adaptive Trials For Comparative Effectiveness Research (CER): “RE-ADAPT”ING ALLHAT (2013) (0)
- PDB13 PHARMACY AND MEDICAL RESOURCE UTILIZATION AMONG INITIAL METFORMIN AND THIAZOLIDINEDIONE PATIENTS (2004) (0)
- PCV15 Social Networks Help Control Hypertension (2012) (0)
- PIN14 HEALTH RESOURCE UTILIZATION IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS (2002) (0)
- Major GI Events among Cox-2 Inhibitor, NSAID, and Aspirin Users: 728 (2005) (0)
- WW13: CHALLENGES IN PERFORMING META ANALYSIS IN HEART FAILURE OUTCOMES RESEARCH (2001) (0)
- A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415. (2020) (0)
- Operation PCOR: A Community Engagement Project Preparing Veterans as Full Partners in PTSD-Related Research (2021) (0)
- Risk and cost of anthracycline-induced cardiotoxicity among breast cancer patients in the United States. (2009) (0)
- (402) Conceptual model of societal burden of non-medical use of prescription opioids/analgesics among patients with chronic pain (2008) (0)
- Table of Contents Examination of Data , Analytical Issues and Proposed Methods for Conducting Comparative Effectiveness Research Using “ Real-World Data ” (2011) (0)
- Radiation oncologist visits and the effect on prostate cancer (PCa) survival among SEER-Medicare patients with stage IV disease. (2011) (0)
- Eliciting Low-Risk Thyroid Cancer Treatment Preferences using Clinical Vignettes: A Pilot Study. (2023) (0)
- PID1: ESTIMATES OF THE INDIRECT COSTS OF HIV AND AIDS IN THE UNITED KINGDOM (1999) (0)
- MAIN OUTCOME MEASURES (1997) (0)
- Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415. (2021) (0)
- Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study (2015) (0)
- PMH46 TREATMENT PERSISTENCE WITH DULOXETINE AND HEALTH CARE COSTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (2010) (0)
- Understanding the experience of living with non-small cell lung cancer (NSCLC): A qualitative study. (2013) (0)
- Patient Characteristics Associated with Use of Monoclonal Antibody Treatment in Women with Metastatic Breast Cancer: A Population-Based Analysis. (2009) (0)
- HT4 PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL: IS IT REALISTIC? (2010) (0)
- Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Report of the ISPOR Drug Cost Task Force - Part I: Issues & Recommendations (2008) (0)
- Algorithm for identifying various second- and third-line chemotherapy regimens in elderly U.S. Medicare patients with metastatic colon cancer. (2013) (0)
- Use of growth factors associated with docetaxel and paclitaxel in patients with early-stage breast cancer in a community oncology center. (2009) (0)
- PIN19 PRESCRIBING DECISIONS IN A UTILITY MODEL (2002) (0)
- PCV35: COMPARABILITY OF PUBLISHED STUDIES ON COST-EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY: DO THE RESULTS HELP THE DECISION-MAKING PROCESS? (2001) (0)
- Abstracts of the ISPOR 18th Annual International Meeting Research. (2013) (0)
- PNL11 AN ECONOMIC EVALUATION OFTRIPTAN PRODUCTS FOR MIGRAINE (2005) (0)
- Predictors of second- and third-line chemotherapy receipt in stage IV colon cancer Medicare beneficiaries. (2013) (0)
- Impact of patient sample on costs of events in pharmacoeconomic models (2008) (0)
- Outcomes after endoscopic local excision of early-stage gastric adenocarcinoma in the United States. (2023) (0)
- Health Plans' Strategies For Managing Outpatient Specialty (2006) (0)
- 1528 An economic evaluation of triptan products for migraine (2005) (0)
- How do first-line treatment and other factors affect the receipt of second-line treatment for elderly metastatic colon cancer patients? (2013) (0)
- Frequency of Second and Third Line Treatment Among Elderly Medicare Stage 4 Colon Cancer Patients (2012) (0)
- PMC36 THE POPULATION IMPACT OF CHEMOTHERAPY IN LATE-STAGE PROSTATE CANCER: A SIMULATION STUDY USING TAX327 AND SEER-MEDICARE DATA (2009) (0)
- PUK25 Role of Health Literacy on Kidney Transplant Patients Immunosuppressant Drugs Information Needs (2012) (0)
- CE4 A Framework for Stakeholder Engagement in Comparative Effectiveness Research (2012) (0)
- PMH1 METABOLIC SYNDROME AND SECOND GENERATION ANTIPSYCHOTICS UTILIZATION—IMPACT OF PSYCHIATRIC COMORBIDITY AND POLYPHARMACY (2010) (0)
- PRS10 TREATMENT COSTS ASSOCIATED WITH COMMUNITY ACQUIRED PNEUMONIA BY COMMUNITY LEVEL OF ANTIMICROBIAL RESISTANCE (2007) (0)
- PCN97 PHYSICIAN REFERRAL PATTERNS AMONG ELDERLY PATIENTS WITH STAGE IV PROSTATE CANCER (PCA): AN ANALYSIS USING SEERMEDICARE DATA (2009) (0)
- Taxane Treatment in Women with Incident Stage IV Breast Cancer. (2009) (0)
- CV2 CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS COMPARED TO OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS: AN OBSERVATIONAL STUDY OF A MEDICAID POPULATION (2004) (0)
- VP02 Are Journal Editors A Barrier To Publication Of Real World Evidence? (2017) (0)
- Characteristics of elderly metastatic prostate cancer (M1 PC) long-term survivors in the SEER Medicare database receiving androgen-deprivation therapy (ADT). (2016) (0)
- Second and Third Line Chemotherapy Regimens in Elderly Medicare Stage 4 Colon Cancer Patients (2012) (0)
- Conceptual Model of Shared Decision Making and Patient Engagement in Neurology (P1.358) (2016) (0)
- Incidence of diagnosed VTE among elderly Americans in the year following stage III or IV colon cancer diagnosis. (2010) (0)
- WH1 BREAST CANCER PATIENTS' PREFERENCES FOR LOCAL AND SYSTEMIC THERAPY (2007) (0)
- Comparative effectiveness and survival benefit of various treatment modalities in HCC: A SEER-Medicare analysis. (2013) (0)
- Age at diagnosis and treatment for prostate cancer (PC) in two distinct integrated health care systems. (2013) (0)
- Oxaliplatin- or irinotecan-based combination therapy versus 5-fluorouracil/leucovorin alone in the treatment of advanced colon cancer patients age 66 and older: An analysis using SEER-Medicare data. (2010) (0)
- A Dynamic Approach for Budget Impact Analysis (BIA) in Oncology: Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC) as an Illustrative Example (2018) (0)
- DIABETES DIABETES CONTROL THROUGH AN EDUCATIONAL INTERVENTION (2014) (0)
- MP78-02 CUMULATIVE INCIDENCE OF SKELETAL RELATED EVENTS IN MEN WITH METASTATIC PROSTATE CANCER BASED ON ALTERNATIVE ALGORITHMS (2014) (0)
- PMH77 ANTIPSYCHOTIC METABOLIC PROPENSITY AND POLYTHERAPY: INFLUENCE ON HOSPITALIZATION (2008) (0)
- Association Between Overall Incremental Cost And Survival Benefit Of Second Line Chemotherapy/Biologics Treatment Among Elderly Medicare Metastatic Colon Cancer Patients (2013) (0)
- PHPI9 MEDICATION NEEDS OF ELDERLY INDIVIDUALS WITHOUT PRESCRIPTION DRUG COVERAGE (2005) (0)
- PCV21 ANTIHYPERTENSIVE DRUG BUDGET IMPACT OF THE ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN THE UK (2006) (0)
- PMH79 PHYSICAL MORBIDITY AMONG PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OFTHE NATIONAL HOSPITAL DISCHARGE REGISTRY (2010) (0)
- Development of effectiveness guidance documents (EGDs) as a stakeholder-driven process for informing study designs for comparative effectiveness research (CER). (2011) (0)
- DB2: INCOME DISPARITY IN DIFFUSION OF ORAL DIABETES THERAPY 1999-2001 (2003) (0)
- Cost-effectiveness analysis of treatment modalities for hepatocellular carcinoma in the SEER-Medicare population. (2012) (0)
- Reply to F. Perrone et al (2012) (0)
- Multidisciplinary physician care and mortality in hepatocellular carcinoma (2013) (0)
- Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. (2022) (0)
- The impact of time of medical oncologist visit on survival among elderly patients with stage IV prostate cancer: An analysis using SEER-Medicare data. (2016) (0)
- Increases in Marylanders' out-of-pocket drug spending outpaced overall drug spending in 2001 by fifteen percentage points. (2004) (0)
- ND3 PRESCRIBING PATTERNS AMONG DEMENTIA PATIENTS AT THE VETERANS AFFAIRS MARYLAND HEALTH CARE SYSTEM (VAMHCS) (2009) (0)
- CV3 MULTI-COUNTRY COMPARISON OF HYPERTENSION COSTS FROM HOSPITALIZATIONS AND AMBULATORY CARE (2002) (0)
- Review of cost–effectiveness studies of pegylated therapies for hepatitis C (2005) (0)
- The cost-effectiveness of transarterial chemoembolization treatments. (2012) (0)
- Linezolid vs. Vancomycin: Re-hospitalization Rates among Patients with Pneumonia, Staphylococcal Infection, and Skin and Soft Tissue Infection (2009) (0)
- HP2 TRENDS IN ANGIOTENSIN II RECEPTOR BLOCKER (ARB) PRESCRIBING AMONG GENERAL PRACTITIONERS IN THE UK (2006) (0)
- PAR18 RACIAL DISPARITIES IN PRESCRIBING OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS OVER OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN A MEDICAID MANAGED CARE POPULATION (2004) (0)
- Common head and neck cancer treatment pathways and associated costs in the U.S. commercial managed care population. (2009) (0)
- PDG1 Comparative Effectiveness and Safety of Pharmaceuticals Assessed in Observational Studies Compared with Randomized Controlled Trials (2020) (0)
- DB4 HEART FAILURE RISK OFTHIAZOLIDINEDIONES INA MEDICAID MANAGED CARE POPULATION (2005) (0)
- Skeletal-related events (SREs), baseline comorbidity, and survival among elderly patients (pts) with metastatic (M1) prostate cancer (PCa) in SEER-Medicare. (2013) (0)
- The effects of age, stage, treatment, and Charlson comorbidity index (CCI) on quality of life after prostate cancer diagnosis in a single cohort. (2013) (0)
- PCN146 Specialty Care and Treatment in Medicare HCC Patients (2012) (0)
- Skeletal-related events (SREs) and survival among elderly patients with stage IV prostate cancer (PCa) in SEER Medicare data. (2014) (0)
- PCV31: ECONOMIC IMPACT OF UNCONTROLLED HYPERTENSION AMONG NSAID USERS (2003) (0)
- 780 DIFFERENCES IN PROVIDER ENCOUNTERS BETWEEN METASTATIC (M1) AND NON-METASTATIC (M0) PROSTATE CANCER (PCA) PATIENTS (2013) (0)
- Chemotherapy Treatment and Survival in Estrogen Receptor Negative Metastatic Breast Cancer: A Population-Based Analysis. (2009) (0)
- Effect of VTE on mortality in patients with stage III colon cancer. (2011) (0)
- An Approach to Identify Delivery of Palliative Radiation Therapy Using Health Care Claims Data: A Proof-of-Concept Application of a Visual Analytics Tool. (2018) (0)
- Costs Of End-Of-Life Treatments Among Elderly Metastatic Colon Cancer Patients (2016) (0)
- PCN40 DISPARITIES IN MEDICAID CANCER EXPENDITURES (2004) (0)
- Quality-of-care data from managed-care organizations. (1997) (0)
- PHP36 HEALTH ECONOMICS DATA: USE AND PERCEIVED VALUE IN U.S. PAYERS' FORMULARY DECISIONS (2009) (0)
- All products can't be the best, can they (2006) (0)
- Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study. (2019) (0)
- Subgroup analysis versus post-hoc analysis. (2001) (0)
- Providing Patients with Cost Information (2015) (0)
- Supporting the validity of outcomes research. (2004) (0)
- COST-OF-ILLNESS STUDIES: CONSIDERATIONS WHEN DESIGNING COI RESEARCH (2016) (0)
- An invitation to the health policy debates. (2008) (0)
- Implementing stakeholder engagement to explore alternative models of consent: An example from the PREP-IT trials (2021) (0)
- Quality versus Cost (2015) (0)
- Pharmaceutical prices and policy (2004) (0)
- Appropriate methodologies for assessing the quality of treatment and the conduct of outcomes research (2006) (0)
- The advent of a Patient-Centered Outcomes Research Institute (2010) (0)
- Innovations to the Management of Multiple Myeloma in the Managed Care Setting (2012) (0)
- Additional file 1: of Understanding preferences for type 2 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods study (2016) (0)
- Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned. (2019) (0)
- The complexity of assessing outcomes of combination therapy. (2003) (0)
- Pharmaceutical use and outcomes in children. (2009) (0)
- Expanding the learning health system model to be health literate (2022) (0)
- Developing a Guide on How to Involve Patients in Research Studies (2020) (0)
- Editorial comment. (2008) (0)
- Additional file 2: of Understanding preferences for type 2 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods study (2016) (0)
- Hidden Cost of Treatment: Side Effects (2015) (0)
- Benefits Improvement and Protection Act’s Impact on Transplantation Rates Among Elderly MEDICARE Beneficiaries With End-Stage Renal Disease (2013) (0)
- Toward Accountable Care: Achieving Value and Integration viaPopulation Health Management (2017) (0)
- A welcome debate on statistical analysis. (2001) (0)
- PNS245 DEVELOPING PRIORITIES FOR THE COMMUNITY ENGAGEMENT TRAINING OF HEALTHCARE PROFESSIONAL STUDENTS (2019) (0)
- Models for Sustaining and Expanding Patient Involvement in PCOR (2014) (0)
- Patient-reported outcomes: D j Vu? (2004) (0)
- Borrowing from other disciplines. (2001) (0)
- Affordability + Clinical Effectiveness = The Value Equation (2015) (0)
- Endpoints in Pain: the Suitability for Health Economic Evaluation of Endpoint Designs in Chronic Pain Studies. (2014) (0)
- Comorbidity Burden And Incremental Cost of Fractures In Medicare Men With Non-Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy (2015) (0)
- AMCP Weighs in on Cost-Effectiveness (2015) (0)
- The importance of motivating junior scholars (2007) (0)
- Expanding the scope and level of evidence in evidence-based medicine (2003) (0)
- Drug discounts for the uninsured. (2003) (0)
- The economics of lipid management. (2001) (0)
- Persistency measurement and cost-effectiveness analysis (2002) (0)
- CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 Diabetes (2022) (0)
- Pharmacoeconomics of NSAIDs: Beyond Bleeds (2015) (0)
- The Use of Cost Effectiveness Analyses by PharmaceuticalBenefit Managers (1995) (0)
- New Conversations About Costs of Cancer Care (2015) (0)
- Information is a good thing (2006) (0)
- Using databases to optimize health care and outcomes research (2004) (0)
- Managing work flow in high enrolling trials: The development and implementation of a sampling strategy in the PREPARE trial (2021) (0)
- Finding Value in Healthcare (2015) (0)
- PROFILE OF OLDER PUBLIC TRANSPORTATION USERS IN THE UNITED STATES: IMPLICATIONS FOR AGE-FRIENDLY COMMUNITIES (2022) (0)
- Joining Forces with Veterans: Veterans’ and Researchers’ Perspectives on Veteran-Centered Engagement Practices (2023) (0)
- Shining Light and Creating Solutions: Health and Social Needs of Older Affordable Housing Residents (2020) (0)
- Attitudes Toward a Pre-authorized Concealed Opioid Taper: A Qualitative Analysis of Patient and Clinician Perspectives (2022) (0)
- Qualitative inquiry from multiple perspectives of barriers and facilitators of oral health care for adults with disabilities. (2022) (0)
- Creation of objective performance criteria among medical devices (2022) (0)
- Moving Beyond "Leaning In"-It Is Time to Reach Out and Partner to Solve the Military Sleep Problem. (2021) (0)
- Archaeology for the People: Community-Based Research, Hands-On Education, and their Place in Archaeology (2019) (0)
- Constructing Health State Descriptions for Low-Risk Thyroid Cancer: Stakeholder Engagement and Formative Qualitative Research (2022) (0)
- Ability of Caprini and Padua Risk-Assessment Models to Predict Venous Thromboembolism in a Nationwide Study (2023) (0)
- Effects in Anemia Management of Dialysis Patients (2007) (0)
- Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis (2022) (0)
- Longitudinal Study of Prevalence of Sodium Abnormalities in Hospitalized Patients With COVID-19 (2021) (0)
- Abnormal Sodium is a Predictor for Respiratory Failure and Mortality in Hospitalized Patients With COVID-19 (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With C. Daniel Mullins?
C. Daniel Mullins is affiliated with the following schools:
